| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2017: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2016: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Outline of Final Research Achievements |
Sorafenib is an anticancer agent which lead to hand-foot syndrome characterized by hyperkeratosis.We speculated that cathepsin C (CTSC) is associated with the pathogenis of hand-foot syndrome. We confirmed CTSC expression in HaCaT（immortal keratinocyte cell line）cells decreased after adding Solafenib to culture medium for HaCaT. Furthermore, we administered Sorafenib CTSC knock out mice and wild type mice each, found that significant hyperkeratosis on soles was seen in CTSC knock out mice compared with wild.
We also researched that IL-4 and IL-13 stimulation increased CTSC expression in keratinocyte. The results will help treatment for hand-foot syndrome.
|
